The board of directors of SSY Group Limited announced that the Group's Doxofylline has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Doxofylline is mainly used in treatment of difficulty in breathing due to bronchial asthma, chronic asthmatic bronchitis and other bronchospasm. In addition, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China issued the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (Year 2022) (2022) (the"National Essential Drug List"), which shall be officially implemented from 1 March 2023.

The Board announced that a total of 96 products of the Group have been included in the National Essential Drug List. Among which, the Group's new product Lacosamide Injection (20ml:0.2g) was included for the first time in "negotiation medicines within agreed period section" and another new product Blonanserin Tablets was transferred to conventional "western medicines section" ()of the National Essential Drug List, which are expected to bring growth in sales of the two new products. Lacosamide Injection is mainly used in combination therapy for partial-onset seizures in epilepsy patients.

Blonanserin Tablets is mainly used in treatment of schizophrenia, and the Group was the first domestic entity in China being approved for drug production and registration for Blonanserin Tablets.